Queen Mary University of London
William Harvey Research Institute
Julia Ramírez is a María Zambrano Research Fellow at the University of Zaragoza, Spain and holds an honorary lectureship in Cardiovascular Data Science at Queen Mary University of London, United Kingdom. Julia received a Ph.D. in Biomedical Engineering from the University of Zaragoza in 2017. The main objective of her PhD was to extract information from the electrocardiogram (ECG) to non-invasively quantify cardiovascular risk. She, then, moved to Queen Mary University of London to investigate the genetics of ECG markers and their role in assessing cardiovascular risk. In January 2022, she returned to the University of Zaragoza thanks to the María Zambrano Scheme for Attracting International Talent. Julia has 55 publications, and her research has been awarded with four postdoctoral fellowships (WHRI-ACADEMY COFUND International Fellowship, 2017, Marie Skłodowska-Curie Individual Fellowship, 2018, by the Marie Curie Actions, H2020, European Commission, "Atracción de Talento Investigador de la Comunidad de Madrid - Modalidad 2" and "Ayuda a la Recualificación Atracción de Talento Internacional María Zambrano"). Her research has been awarded with three Young Investigator Awards (2013, 2014 and 2016), two Clinical Needs Translational Awards (2018 and 2019) and three mobility grants (2012, 2015 and 2016).

Presenter of 1 Presentation

PREDICTION OF CORONARY ARTERY DISEASE AND MAJOR ADVERSE CARDIOVASCULAR EVENTS USING CLINICAL AND GENETIC RISK SCORES FOR CARDIOVASCULAR RISK FACTORS

Session Type
Workshop - Risk factors
Date
Mon, 23.05.2022
Session Time
11:00 - 12:30
Room
Rodolfo Paoletti - Red room
Lecture Time
11:50 - 12:00

Abstract

Background and Aims

Risk stratification of coronary artery disease (CAD) and major adverse cardiovascular events (MACE) remains suboptimal. CAD genetic risk scores (GRSs) predict risk independently from the QRISK3 score. We assessed the added value of GRSs for cardiovascular traits (CV GRSs).

Methods

We used data from 379,581 participants in the UK Biobank without known cardiovascular conditions (follow-up 11.3 years, 3.3% CAD cases, 5.2% MACE cases). In a training subset (50%) we built (1) QRISK3; (2) QRISK3 and an established CAD GRS; and (3) QRISK3, the CAD GRS and the CV GRSs. In an independent subset (50%), we evaluated their performance using the area under the curve (AUC) and odds ratio (ORs). We, then, repeated the analyses with (4) CAD GRS; and (5) CAD GRS and CV GRSs.

Results

For CAD, the combination of QRISK3 and the CAD GRS had a better performance than QRISK3 alone (AUC of 0.767 versus 0.756, P = 3.0x10-7, OR of 5.47 versus 4.82). Adding the CV GRSs did not significantly improve risk stratification. When only looking at genetic information, the combination of CV GRSs and the CAD GRS had a better performance than the CAD GRS alone (AUC of 0.635 versus 0.624, P = 1.4x10-13, OR of 2.17 versus 2.07). Similar results were obtained for MACE.

Conclusions

The inclusion of CV GRSs to QRISK3 and an established CAD GRS does not improve CAD or MACE risk stratification. However, their combination only with the CAD GRS increases prediction performance indicating potential use before the advanced development of conventional CV risk factors.

Hide